UnitedHealthcare and Aetna Narrow Some Medicare Advantage Networks for 2027
UnitedHealthcare and Aetna say more 2027 Medicare Advantage plans will limit provider access, making annual network checks especially important during open enrollment.
Foghorn and Lilly End FHD-909 Program; Biotech Plans 40% Workforce Cut
Foghorn Therapeutics and Eli Lilly will not advance the cancer drug FHD-909 after Phase 1 data review, and Foghorn says it will reduce its workforce by about 40%.
7UP Tropical Zero Sugar Recall: Check These Utah Lot Codes
More than 77,000 cans of 7UP Tropical are under a Utah recall because some full-sugar soda was packaged in Zero Sugar cans. Check the UPC, lot code and best-by date.
Lady A Singer Charles Kelley Announces Multiple Myeloma Diagnosis
Lady A co-founder Charles Kelley publicly disclosed a multiple myeloma diagnosis, saying he feels hopeful and plans to keep working during treatment.
Mezzetta Recalls One Lot of 32-Ounce Golden Greek Peperoncini
Mezzetta recalled 32-ounce Golden Greek Peperoncini jars with SKU 10106328 and lot 720106 over a potential foreign-object concern.
Graziers Raw Milk Cheese Recalled Nationwide Amid E. coli Investigation
Sierra Nevada Cheese Company recalled all Graziers raw milk cheese on the market. The FDA and CDC are investigating 13 E. coli illnesses across nine states.
WHO Discussion Asks Who Controls Traditional Medicine Knowledge in the AI Era
WHO and partners examined consent, attribution and benefit-sharing as AI research uses traditional medicine knowledge. The discussion did not create a new global rule.
South Africa orders safety audits and case reviews after killings of women
President Cyril Ramaphosa announced 60-day safety audits and 90-day reviews of unresolved gender-based violence cases after at least 11 women were killed in Ekurhuleni.
UniQure’s Four-Year Huntington’s Gene-Therapy Result Misses Statistical Threshold
UniQure's 48-month AMT-130 analysis favored treatment but missed statistical significance on the composite disease scale; the trial remains under FDA review.
FDA Approves Emcitate, First Treatment for MCT8 Deficiency Symptoms
The FDA approved Emcitate for excess thyroid hormone in adults and children with MCT8 deficiency, the first U.S.-approved therapy for its symptoms.